Catalent, Inc. (NYSE: CTLT) Stock Competitors & Peer Comparison
See CTLT's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CTLT and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| TAK | $17.42 | -0.37% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.04 | +1.54% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.25 | -0.16% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $22.60 | -0.59% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.42 | -0.24% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.90 | +0.22% | 6.6B | 16.93 | $5.95 | N/A |
| AMRX | $17.84 | +4.33% | 5.6B | 19.62 | $0.90 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
CTLT vs TAK Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TAK trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TAK's P/E ratio is 12.52. In terms of profitability, CTLT's ROE is -0.25%, compared to TAK's ROE of +0.02%. Regarding short-term risk, CTLT is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check TAK's competition here
Haleon plc (NYSE: HLN)
CTLT vs HLN Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas HLN's P/E ratio is 18.28. In terms of profitability, CTLT's ROE is -0.25%, compared to HLN's ROE of +0.17%. Regarding short-term risk, CTLT is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
CTLT vs TEVA Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TEVA trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TEVA's P/E ratio is 12.54. In terms of profitability, CTLT's ROE is -0.25%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, CTLT is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
CTLT vs VTRS Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while VTRS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas VTRS's P/E ratio is 6.39. In terms of profitability, CTLT's ROE is -0.25%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, CTLT is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
CTLT vs ITCI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CTLT's ROE is -0.25%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, CTLT is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
CTLT vs ELAN Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ELAN trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ELAN's P/E ratio is 20.91. In terms of profitability, CTLT's ROE is -0.25%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, CTLT is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
CTLT vs RDY Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while RDY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas RDY's P/E ratio is 20.30. In terms of profitability, CTLT's ROE is -0.25%, compared to RDY's ROE of +0.09%. Regarding short-term risk, CTLT is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
CTLT vs LNTH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while LNTH trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas LNTH's P/E ratio is 16.93. In terms of profitability, CTLT's ROE is -0.25%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, CTLT is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
CTLT vs AMRX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas AMRX's P/E ratio is 19.62. In terms of profitability, CTLT's ROE is -0.25%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, CTLT is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
CTLT vs INDV Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas INDV's P/E ratio is 10.61. In terms of profitability, CTLT's ROE is -0.25%, compared to INDV's ROE of -2.16%. Regarding short-term risk, CTLT is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
CTLT vs SUPN Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SUPN trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SUPN's P/E ratio is 15.64. In terms of profitability, CTLT's ROE is -0.25%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, CTLT is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
CTLT vs RGC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while RGC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas RGC's P/E ratio is -356.34. In terms of profitability, CTLT's ROE is -0.25%, compared to RGC's ROE of -2.32%. Regarding short-term risk, CTLT is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
CTLT vs BHC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while BHC trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas BHC's P/E ratio is 1.58. In terms of profitability, CTLT's ROE is -0.25%, compared to BHC's ROE of +0.89%. Regarding short-term risk, CTLT is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
CTLT vs DCPH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CTLT's ROE is -0.25%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CTLT is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
CTLT vs HCM Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while HCM trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas HCM's P/E ratio is 4.59. In terms of profitability, CTLT's ROE is -0.25%, compared to HCM's ROE of +0.01%. Regarding short-term risk, CTLT is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
CTLT vs AVDL Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, CTLT's ROE is -0.25%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, CTLT is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
CTLT vs EMBCV Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CTLT's ROE is -0.25%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, CTLT is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
CTLT vs DVAX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas DVAX's P/E ratio is -41.89. In terms of profitability, CTLT's ROE is -0.25%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, CTLT is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
CTLT vs PRGO Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas PRGO's P/E ratio is 5.07. In terms of profitability, CTLT's ROE is -0.25%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, CTLT is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
CTLT vs ANIP Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ANIP trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ANIP's P/E ratio is 9.14. In terms of profitability, CTLT's ROE is -0.25%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, CTLT is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
CTLT vs TARO Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TARO's P/E ratio is 30.05. In terms of profitability, CTLT's ROE is -0.25%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CTLT is similarly volatile compared to TARO. This indicates similar risk in terms of short-term price fluctuations for CTLT.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
CTLT vs HROW Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while HROW trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas HROW's P/E ratio is 437.33. In terms of profitability, CTLT's ROE is -0.25%, compared to HROW's ROE of -1.04%. Regarding short-term risk, CTLT is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
CTLT vs PAHC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas PAHC's P/E ratio is 11.54. In terms of profitability, CTLT's ROE is -0.25%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, CTLT is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
CTLT vs ALVO Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ALVO trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ALVO's P/E ratio is -11.79. In terms of profitability, CTLT's ROE is -0.25%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, CTLT is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
CTLT vs CRON Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas CRON's P/E ratio is 30.10. In terms of profitability, CTLT's ROE is -0.25%, compared to CRON's ROE of +0.06%. Regarding short-term risk, CTLT is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
CTLT vs ETON Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ETON trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ETON's P/E ratio is -594.00. In terms of profitability, CTLT's ROE is -0.25%, compared to ETON's ROE of -0.06%. Regarding short-term risk, CTLT is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
CTLT vs PCRX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while PCRX trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas PCRX's P/E ratio is 9.12. In terms of profitability, CTLT's ROE is -0.25%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, CTLT is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
CTLT vs PETQ Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CTLT's ROE is -0.25%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, CTLT is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
CTLT vs AMPH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while AMPH trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas AMPH's P/E ratio is 6.82. In terms of profitability, CTLT's ROE is -0.25%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, CTLT is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
CTLT vs COLL Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while COLL trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas COLL's P/E ratio is 3.26. In terms of profitability, CTLT's ROE is -0.25%, compared to COLL's ROE of +0.16%. Regarding short-term risk, CTLT is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
CTLT vs EVO Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas EVO's P/E ratio is -3.09. In terms of profitability, CTLT's ROE is -0.25%, compared to EVO's ROE of -0.24%. Regarding short-term risk, CTLT is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
CTLT vs IRWD Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas IRWD's P/E ratio is 5.54. In terms of profitability, CTLT's ROE is -0.25%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, CTLT is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
CTLT vs BDSI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CTLT's ROE is -0.25%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CTLT is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
CTLT vs EOLS Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while EOLS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas EOLS's P/E ratio is -25.71. In terms of profitability, CTLT's ROE is -0.25%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, CTLT is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
CTLT vs AQST Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas AQST's P/E ratio is -6.93. In terms of profitability, CTLT's ROE is -0.25%, compared to AQST's ROE of +2.44%. Regarding short-term risk, CTLT is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
CTLT vs TLRY Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TLRY trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TLRY's P/E ratio is -4.32. In terms of profitability, CTLT's ROE is -0.25%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, CTLT is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
CTLT vs CGC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas CGC's P/E ratio is -0.62. In terms of profitability, CTLT's ROE is -0.25%, compared to CGC's ROE of -0.33%. Regarding short-term risk, CTLT is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
CTLT vs KMDA Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas KMDA's P/E ratio is 19.66. In terms of profitability, CTLT's ROE is -0.25%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, CTLT is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
CTLT vs TKNO Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TKNO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TKNO's P/E ratio is -23.84. In terms of profitability, CTLT's ROE is -0.25%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, CTLT is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
CTLT vs ALIM Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CTLT's ROE is -0.25%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, CTLT is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
CTLT vs EMBC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while EMBC trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas EMBC's P/E ratio is 1.83. In terms of profitability, CTLT's ROE is -0.25%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, CTLT is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
CTLT vs LNDC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CTLT's ROE is -0.25%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, CTLT is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
CTLT vs ACB Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ACB trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ACB's P/E ratio is -7.80. In terms of profitability, CTLT's ROE is -0.25%, compared to ACB's ROE of -0.21%. Regarding short-term risk, CTLT is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
CTLT vs ORGO Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ORGO trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ORGO's P/E ratio is 60.33. In terms of profitability, CTLT's ROE is -0.25%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, CTLT is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
CTLT vs TYHT Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CTLT's ROE is -0.25%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, CTLT is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
CTLT vs SIGA Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SIGA trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SIGA's P/E ratio is 10.63. In terms of profitability, CTLT's ROE is -0.25%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, CTLT is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
CTLT vs OGI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas OGI's P/E ratio is -4.96. In terms of profitability, CTLT's ROE is -0.25%, compared to OGI's ROE of -0.07%. Regarding short-term risk, CTLT is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
CTLT vs LFCR Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas LFCR's P/E ratio is -4.46. In terms of profitability, CTLT's ROE is -0.25%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, CTLT is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
CTLT vs REPH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas REPH's P/E ratio is -8.04. In terms of profitability, CTLT's ROE is -0.25%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CTLT is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
CTLT vs DERM Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while DERM trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas DERM's P/E ratio is -17.38. In terms of profitability, CTLT's ROE is -0.25%, compared to DERM's ROE of -0.36%. Regarding short-term risk, CTLT is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
CTLT vs CRDL Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas CRDL's P/E ratio is -5.41. In terms of profitability, CTLT's ROE is -0.25%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, CTLT is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
CTLT vs THTX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas THTX's P/E ratio is -28.83. In terms of profitability, CTLT's ROE is -0.25%, compared to THTX's ROE of +0.17%. Regarding short-term risk, CTLT is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
CTLT vs ASRT Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ASRT's P/E ratio is -7.10. In terms of profitability, CTLT's ROE is -0.25%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, CTLT is similarly volatile compared to ASRT. This indicates similar risk in terms of short-term price fluctuations for CTLT.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
CTLT vs CPIX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while CPIX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas CPIX's P/E ratio is -19.90. In terms of profitability, CTLT's ROE is -0.25%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, CTLT is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
CTLT vs SCTL Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CTLT's ROE is -0.25%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CTLT is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
CTLT vs BGM Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas BGM's P/E ratio is -1.01. In terms of profitability, CTLT's ROE is -0.25%, compared to BGM's ROE of -0.07%. Regarding short-term risk, CTLT is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
CTLT vs PROC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas PROC's P/E ratio is 1.53. In terms of profitability, CTLT's ROE is -0.25%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CTLT is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
CTLT vs OPTN Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CTLT's ROE is -0.25%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, CTLT is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
CTLT vs ZOM Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CTLT's ROE is -0.25%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, CTLT is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
CTLT vs GRVI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CTLT's ROE is -0.25%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, CTLT is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
CTLT vs ZYBT Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, CTLT's ROE is -0.25%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, CTLT is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
CTLT vs TLPH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TLPH trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TLPH's P/E ratio is -4.52. In terms of profitability, CTLT's ROE is -0.25%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, CTLT is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
CTLT vs ZYNE Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CTLT's ROE is -0.25%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CTLT is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
CTLT vs SSIC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CTLT's ROE is -0.25%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, CTLT is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
CTLT vs VLNS Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CTLT's ROE is -0.25%, compared to VLNS's ROE of N/A. Regarding short-term risk, CTLT is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
CTLT vs DRRX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas DRRX's P/E ratio is -4.44. In terms of profitability, CTLT's ROE is -0.25%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, CTLT is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
CTLT vs INCR Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while INCR trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas INCR's P/E ratio is -2.23. In terms of profitability, CTLT's ROE is -0.25%, compared to INCR's ROE of -0.09%. Regarding short-term risk, CTLT is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
CTLT vs JUPW Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CTLT's ROE is -0.25%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, CTLT is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
CTLT vs CPHI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while CPHI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas CPHI's P/E ratio is -1.72. In terms of profitability, CTLT's ROE is -0.25%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, CTLT is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
CTLT vs QLI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas QLI's P/E ratio is -4.92. In terms of profitability, CTLT's ROE is -0.25%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CTLT is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
CTLT vs HEXO Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CTLT's ROE is -0.25%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CTLT is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
CTLT vs RMTI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while RMTI trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas RMTI's P/E ratio is -7.42. In terms of profitability, CTLT's ROE is -0.25%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, CTLT is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
CTLT vs AYTU Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas AYTU's P/E ratio is -1.23. In terms of profitability, CTLT's ROE is -0.25%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, CTLT is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
CTLT vs TXMD Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas TXMD's P/E ratio is 105.96. In terms of profitability, CTLT's ROE is -0.25%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, CTLT is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
CTLT vs CYTH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas CYTH's P/E ratio is -0.80. In terms of profitability, CTLT's ROE is -0.25%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, CTLT is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
CTLT vs EVOK Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas EVOK's P/E ratio is -7.97. In terms of profitability, CTLT's ROE is -0.25%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, CTLT is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
CTLT vs OPTH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while OPTH trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas OPTH's P/E ratio is -17.38. In terms of profitability, CTLT's ROE is -0.25%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, CTLT is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
CTLT vs ACRX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CTLT's ROE is -0.25%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, CTLT is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CTLT vs BFRIW Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, CTLT's ROE is -0.25%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, CTLT is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CTLT vs COSM Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas COSM's P/E ratio is -0.29. In terms of profitability, CTLT's ROE is -0.25%, compared to COSM's ROE of -0.96%. Regarding short-term risk, CTLT is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
CTLT vs AGRX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CTLT's ROE is -0.25%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, CTLT is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
CTLT vs NLTX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CTLT's ROE is -0.25%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, CTLT is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
CTLT vs LCI Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas LCI's P/E ratio is -0.04. In terms of profitability, CTLT's ROE is -0.25%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CTLT is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
CTLT vs ADMP Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ADMP's P/E ratio is -0.08. In terms of profitability, CTLT's ROE is -0.25%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, CTLT is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
CTLT vs YCBD Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas YCBD's P/E ratio is -1.49. In terms of profitability, CTLT's ROE is -0.25%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, CTLT is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
CTLT vs GELS Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas GELS's P/E ratio is -1.14. In terms of profitability, CTLT's ROE is -0.25%, compared to GELS's ROE of -0.25%. Regarding short-term risk, CTLT is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
CTLT vs MNK Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas MNK's P/E ratio is -0.44. In terms of profitability, CTLT's ROE is -0.25%, compared to MNK's ROE of -0.36%. Regarding short-term risk, CTLT is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
CTLT vs FLGC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas FLGC's P/E ratio is -0.19. In terms of profitability, CTLT's ROE is -0.25%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, CTLT is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
CTLT vs UPC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while UPC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas UPC's P/E ratio is -0.75. In terms of profitability, CTLT's ROE is -0.25%, compared to UPC's ROE of -0.03%. Regarding short-term risk, CTLT is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
CTLT vs SBFM Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SBFM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SBFM's P/E ratio is -0.20. In terms of profitability, CTLT's ROE is -0.25%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, CTLT is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
CTLT vs PLXP Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas PLXP's P/E ratio is -0.22. In terms of profitability, CTLT's ROE is -0.25%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, CTLT is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
CTLT vs SHPH Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SHPH trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SHPH's P/E ratio is -0.20. In terms of profitability, CTLT's ROE is -0.25%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, CTLT is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
CTLT vs ATNX Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas ATNX's P/E ratio is -0.02. In terms of profitability, CTLT's ROE is -0.25%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, CTLT is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
CTLT vs SNOA Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SNOA's P/E ratio is -1.16. In terms of profitability, CTLT's ROE is -0.25%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, CTLT is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
CTLT vs PROCW Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas PROCW's P/E ratio is N/A. In terms of profitability, CTLT's ROE is -0.25%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, CTLT is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
CTLT vs RDHL Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas RDHL's P/E ratio is 0.12. In terms of profitability, CTLT's ROE is -0.25%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, CTLT is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
CTLT vs SXTC Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while SXTC trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas SXTC's P/E ratio is 1.18. In terms of profitability, CTLT's ROE is -0.25%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, CTLT is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
CTLT vs YCBD-PA Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, CTLT's ROE is -0.25%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, CTLT is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for CTLT.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
CTLT vs CYTHW Comparison August 2026
Catalent, Inc. (NYSE: CTLT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTLT stands at 11.5B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, CTLT is priced at $63.48 on the NYSE, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTLT currently has a P/E ratio of -27.84, whereas CYTHW's P/E ratio is N/A. In terms of profitability, CTLT's ROE is -0.25%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, CTLT is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for CTLT.Check CYTHW's competition here